Supporting materials to the BMJ paper on the economic evaluation of the DiGEM study
(J. Simon, A. Gray, P. Clarke, A. Wade, A. Neil, A. Farmer on behalf of the Diabetes Glycaemic Education and Monitoring Trial Group. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; doi:10.1136/bmj.39526.674873.BE)
Supplementary information on the length of contacts with nurses (Table A), the variable ‘other healthcare costs’ (Table B) and the distribution of the EuroQol EQ-5D answers (Table C) can be accessed here.
Appendix: Lifetime extrapolation of data from the randomised controlled DiGEM trial
To estimate the long term cost effectiveness of self monitoring of blood glucose in addition to standardised usual care for non-insulin treated type 2 diabetes, we carried out a secondary analysis of the randomised controlled diabetes glycaemic education and monitoring (DiGEM) trial data predicting the lifetime quality adjusted life expectancy and diabetes complication costs. The methods and the results of the analysis can be accessed here.